Marilyn E Levi

Learn More
BACKGROUND Cytomegalovirus (CMV) disease remains an important problem in solid-organ transplant recipients, with the greatest risk among donor CMV-seropositive, recipient-seronegative (D(+)/R(-))(More)
Infections account for 15% to 20% of deaths in transplant recipients; thus, rapid and appropriate therapeutic intervention is required. However, many anti-microbial agents can interact significantly(More)